[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Melinta Therapeutics Inc - Strategic SWOT Analysis Review

December 2021 | 32 pages | ID: M20CD7DDBE7EN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Melinta Therapeutics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Melinta Therapeutics Inc (Melinta) is a biopharmaceutical company that focuses on the development of novel anti-infectives for the treatment of various bacterial infections. Its marketed portfolio encompasses antibiotics for the treatment of serious bacterial infections including acute bacterial skin and skin structure infections (ABSSSI), complicated urinary tract infections (cUTI), and for the prevention and treatment of other serious infections that are caused by susceptible bacteria. The company is also evaluating delafloxacin for the treatment of serious community-acquired bacterial pneumonia (CABP), meropenem and vaborbactam, oritavancin, and minocycline. Melinta's products and pipeline candidates are built on ribosome platform licensed from Yale University. Melinta is headquartered in New Haven, Connecticut, the US.

Melinta Therapeutics Inc Key Recent Developments

Oct 25,2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
Jul 06,2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
Jun 29,2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer
Mar 29,2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer
Nov 16,2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Melinta Therapeutics Inc - Key Facts
Melinta Therapeutics Inc - Key Employees
Melinta Therapeutics Inc - Key Employee Biographies
Melinta Therapeutics Inc - Major Products and Services
Melinta Therapeutics Inc - History
Melinta Therapeutics Inc - Company Statement
Melinta Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Melinta Therapeutics Inc - Business Description
Melinta Therapeutics Inc - Corporate Strategy
Melinta Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Melinta Therapeutics Inc - Strengths
Melinta Therapeutics Inc - Weaknesses
Melinta Therapeutics Inc - Opportunities
Melinta Therapeutics Inc - Threats
Melinta Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Melinta Therapeutics Inc, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Oct 25, 2021: Melinta Therapeutics Announces Appointment of Doug Girgenti as Vice President of Drug Development
Jul 06, 2021: Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy
Jun 29, 2021: Melinta Therapeutics Announces Appointment of Susan Blum as Chief Financial Officer
Mar 29, 2021: Melinta Therapeutics Announces Appointment of John Harlow as Chief Commercial Officer
Nov 16, 2020: Melinta Therapeutics announces appointment of Kristen Allgor as Chief Human Resources Officer
Aug 03, 2020: Melinta Therapeutics announces appointment of Christine Ann Miller as President and Chief Executive Officer
Apr 20, 2020: Melinta Therapeutics successfully completes financial restructuring
Feb 13, 2020: Melinta Therapeutics announces court approval of chapter 11 bidding procedures

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Melinta Therapeutics Inc, Key Facts
Melinta Therapeutics Inc, Key Employees
Melinta Therapeutics Inc, Key Employee Biographies
Melinta Therapeutics Inc, Major Products and Services
Melinta Therapeutics Inc, History
Melinta Therapeutics Inc, Subsidiaries
Melinta Therapeutics Inc, Key Competitors
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Melinta Therapeutics Inc, Recent Deals Summary

LIST OF FIGURES

Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Melinta Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


More Publications